Advanced Centre for Treatment Research & Education in Cancer

Science Sparks @ ACTREC
25 November 2024	Vol. No. 13 ; Issue No.657

Publications

1. Ghorai A, Singh B, Dutt S (2024). Bi-phasic DNA damage and non-canonical replication stress response govern radiation-induced senescence in Glioblastoma. Journal of Cell Science.

2. El Ayachi Z, Gabro A, Camprodon G, Chopra S, Maingon P, Chargari C (2024). Transformative clinical trials in gynaecologic radiation oncology in 2023-2024: Shaping modern treatment practices. Cancer/Radiothérapie.

Site of the Week

MODBASE is a database of annotated protein structure models. It also contains information about putative ligand binding sites, SNP annotation, and protein-protein interactions.

Interesting Reads

Huang CX, Lao XM, Wang XY, Ren YZ, Lu YT, Shi W, Wang YZ, Wu CY, Xu L, Chen MS, Gao Q, Liu L, Wei Y, Kuang DM. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell. 2024

Video of the Week

Oesophageal Cancer Treatment; The Importance of Quality of Life

Upcoming Events

12th International Conference of Laboratory Animal Scientists' Association (LASA), India

Pre Conference Workshop November 28, 2024 Conference 29-30th November 2024

At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai & CIDCO Convention Centre, Vashi, Navi Mumbai.

20th National Research Scholars Meet

11th - 12th December, 2024

At ACTREC, Tata Memorial Centre, Kharghar

13th Annual Hands-on Workshop "In-vivo Preclinical Imaging & Drug Discovery"

December 16-18, 2024

At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai

Do You Know?

In ,1989 US FDA approved Carboplatin, a derivative of cisplatin, for chemotherapy.

Cancer News

Study reveals how glioblastoma evades treatment; identifies potential new treatment strategy.

MedicalXpress, 21/11/2024

A new study explains why glioblastoma, one of the most aggressive forms of brain cancer, becomes resistant to treatment, and introduces a new approach that paves the way for more personalized treatment strategies for patients with this deadly brain tumor...

Trial results support SBRT as a standard option for some prostate cancers.

National Cancer Institute, 21/11/2024

SBRT very precisely targets radiation to the tumor while minimizing exposure to normal tissue, allowing for the delivery of a much higher radiation dose per session and, therefore, far fewer treatment days...

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer.

News-Medical, 19/11/2024

Preclinical findings from this study shows safety as well as complete and durable antitumor responses in a subset of HER2+ tumors. Based on these promising results, a first-in-human phase 1 clinical trial is currently in the approval process for evaluating this novel therapy in patients...

2024 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)